Publications by authors named "S Cacciapuoti"
Article Synopsis
- A fixed-dose combination of calcipotriene and betamethasone dipropionate is the only approved topical therapy for treating psoriasis.
- Experts emphasize the need for more evidence to establish the best use of this treatment in clinical settings.
- Clinical experiences indicate that Cal/BD foam effectively improves outcomes and quality of life for patients with mild-to-moderate psoriasis when used with systemic treatments.
Background: Psoriasis may significantly impact on patients' health related quality of life (HRQoL). Clinical assessment has been combined with HRQoL scores to evaluate the ways that cutaneous disease is a burden to patients. Tildrakizumab is a humanized IgG1 monoclonal antibody targeting interleukin-23 p19 and is approved for the management of moderate-to-severe plaque psoriasis.
View Article and Find Full Text PDFBackground: Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab.
Methods: This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement.
Article Synopsis
- The intersection of artificial intelligence (AI) and medicine has led to significant advancements in healthcare, particularly in the field of dermatology.
- A review of 20 research papers highlighted various applications of ChatGPT, an AI tool, in dermatology, which includes enhancements in clinical practice and patient support.
- ChatGPT is positioned as a key player in modern healthcare, helping to bridge gaps in communication and knowledge sharing between patients and clinicians.
Article Synopsis
- Novel biologics like tildrakizumab are being assessed for their effectiveness in treating psoriasis in challenging areas, focusing on patients with moderate-to-severe symptoms.
- A study of 76 patients showed significant improvement in psoriasis severity scores after 16 weeks of treatment, highlighting the drug's potential benefits.
- The findings suggest that tildrakizumab is effective and safe for managing difficult-to-treat psoriasis and related itching, with quick results.